Porto-based PFx Biotech, a startup focused on developing allergy-free human milk proteins using precision fermentation, has successfully closed a €2.5 million Seed funding round. The round was led by Buenavista Equity Partners, with participation from EIT Food and Beta Capital. This investment, coupled with a recent €2.5 million grant from the EIC Accelerator, will enable PFx Biotech to scale up Lactoferrin production, establish new labs, and expand its team.
PFx Biotech's innovative technology aims to create sustainable, non-GMO, and allergy-free nutritional solutions derived from human milk proteins. These proteins are intended for use in various products, including infant formula, sports nutrition, and elderly nutrition, catering to a wide range of dietary needs and preferences. The company's platform utilizes precision fermentation to produce highly bioactive human milk proteins, offering a compelling alternative to traditional methods.
The funding will be instrumental in advancing PFx Biotech's precision fermentation platform and bringing its allergy-free human milk protein products closer to market. The company's leadership team expresses confidence in its ability to reshape the food system with its biology-driven solutions, and the investors share this vision, recognizing the significant potential of PFx Biotech's technology.
The successful funding round underscores the growing interest in sustainable and innovative food technologies, particularly in the area of precision fermentation. PFx Biotech's progress positions it as a key player in the future of nutrition, offering healthier and more accessible options for consumers worldwide.
